Haixiang Cao

Statistics

Publications

Citations

246

H-Index

Active since

2009

Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College(Current)

Dalian Medical University

Zhongshan Hospital

Peking University People's Hospital

Fudan University

Haixiang Cao is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in pharmacology, medicine, and molecular pharmacology.

ORCID

Publications per year

2009–2021

Publications

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

Mei Dong, Zhiqiang Ning, Pu-yuan Xing et al. · Cancer Chemotherapy and Pharmacology · 2012 · 122 citations

Medicine, Oncology, Pharmacology +11

Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)

Linong Ji, Weihong Song, Hui Fang et al. · Science Bulletin · 2021 · 63 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)

Weiping Jia, Jianhua Ma, Heng Miao et al. · Science Bulletin · 2021 · 46 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

Mei Dong, Zhengwen Ning, Michael Newman et al. · Journal of Clinical Oncology · 2009 · 15 citations

Medicine, Oncology, Pharmacology +14

1–4 of 4